金刚藤胶囊联合头孢西丁钠注射液治疗盆腔炎临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R711.7

基金项目:


Clinical Study on Jingangteng Capsules Combined with Cefoxitin Sodium for Injection in the Treatment of Pelvic Inflammatory Disease
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察金刚藤胶囊联合头孢西丁钠注射液治疗盆腔炎的临床疗效及对血清微小核糖核 酸(miR-34a)、沉默信息调节因子1(SIRT1) 水平的影响。方法:采用随机数字表法将94 例盆腔炎患者分为 对照组、观察组各47 例。对照组给予头孢西丁钠注射液治疗,观察组给予金刚藤胶囊联合头孢西丁钠注射液 治疗,2 组均治疗2 周。比较2 组治疗前后中医证候积分及血清miR-34a、SIRT1 水平;比较2 组治疗前后盆 腔积液量、C-反应蛋白(CRP)、白细胞计数(WBC)、中性粒细胞计数(NEUT);比较2 组症状(下腹疼 痛、白带量多、发热、下腹坠胀) 消退时间;评估2 组临床效果及不良反应发生情况。结果:对照组总有效率 80.85%,低于观察组95.74%(P<0.05)。观察组下腹疼痛、白带量多、发热、下腹坠胀消退时间均较对照组 缩短(P<0.05)。2 组治疗后中医证候积分、盆腔积液量、CRP、WBC、NEUT 及血清miR-34a 水平均较治疗 前降低(P<0.05),血清SIRT1 升高(P<0.05);观察组治疗后中医证候积分、盆腔积液量、CRP、WBC、 NEUT 及血清miR-34a 水平均低于对照组(P<0.05),血清SIRT1 水平高于对照组(P<0.05)。2 组不良反应 发生率比较,差异无统计学意义(P>0.05)。结论:金刚藤胶囊联合头孢西丁钠注射液治疗盆腔炎疗效确切, 能降低患者血清miR-34a 水平,升高SIRT1 水平,降低炎症反应,安全性较高。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Jingangteng Capsules combined with Cefoxitin Sodium Injection in the treatment of pelvic inflammatory disease and its effect on the levels of microRNA- 34 (miR- 34) and silent information regulator 1 (SIRT1) in serum. Methods:A total of 94 cases of patients with pelvic inflammatory disease were divided into the control group and the observation group according to the random number table method, with 47 cases in each group. The control group was treated with Cefoxitin Sodium Injection, and the observation group was treated with Jingangteng Capsules combined with Cefoxitin Sodium Injection. Both groups were treated for 2 weeks. Traditional Chinese medicine (TCM) syndrome scores and the levels of miR-34a and SIRT1 in serum were compared before and after treatment between the two groups. The pelvic fluid volume, C- reactive protein (CRP), white blood cell count (WBC),and neutrophil count (NEUT) were compared before and after treatment between the two groups; the disappearance time of symptoms (lower abdominal pain, excessive vaginal discharge, fever, and down-bearing pain in the lower abdomen) were compared between the two groups. Clinical effects and the incidence of adverse reactions were evaluated in the two groups. Results: The total effective rate was 80.85% in the control group,lower than that of 95.74% in the control group (P<0.05). The disappearance time of lower abdominal pain, excessive vaginal discharge, fever, and down- bearing pain in the lower abdomen in the observation group was shorter than that in the control group (P<0.05). TCM syndrome scores,pelvic fluid volume,CRP,WBC,NEUT,and the levels of serum miR-34a after treatment in the two groups were decreased when compared with those before treatment (P<0.05),and serum SIRT1 was increased (P<0.05);TCM syndrome scores,pelvic fluid volume,CRP,WBC,NEUT,and the levels of serum miR- 34a after treatment in the observation group were lower than those in the control group (P< 0.05),and serum SIRT1 in the observation group was higher than that in the control group (P<0.05). There was no significant difference being found in the comparison of the incidence of adverse reactions between the two groups (P>0.05). Conclusion:Jingangteng Capsules combined with Cefoxitin Sodium Injection has a definite curative effect in the treatment of pelvic inflammatory disease and can reduce the level of serum miR-34 and inflammatory responses and increase SIRT1 level,with high safety.

    参考文献
    相似文献
    引证文献
引用本文

郑凤霞,马云飞,刘光新.金刚藤胶囊联合头孢西丁钠注射液治疗盆腔炎临床研究[J].新中医,2023,55(23):153-157

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-12-13
  • 出版日期:
文章二维码